Health News Releases

  • Today May 17
BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton W
May 15, 15:30
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
BeOne Medicines Ltd. (https://beonemedicines.com/) (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has gr
Aster Guardians Global Nursing Awards 2026 - Top 10 Finalists (Photo: AETOSWire)
May 15, 11:30
Aster Guardians Global Nursing Award Announces Top 10 Finalists for 2026
On the occasion of International Nurses Day, Aster DM Healthcare has announced the Top 10 finalists for the fifth edition of the Aster Guardians Global Nursing Award 2026, selected from over 134,000 r
Signing ceremony with imec held on April 9
May 14, 10:10
Rigaku Accelerates Next-generation Semiconductor Metrology Development Leveraging World-Class Research Infrastructure
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced the
May 14, 09:30
Angelalign Technology Inc. (6699.HK) Applauds European Court Rejection of Patent Infringement Claim
Angelalign Technology Inc. (6699.HK) (“Angel”) (http://www.angelaligner.com) today said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by A
Oral B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability Focused Oral Hea
May 13, 16:26
Oral‑B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability‑Focused Oral Health Studies
Oral B today announces The Big Rethink 2026, the next evolution of its flagship oral health inclusion programme, developed in partnership with the International Association for Disability and Oral Hea
May 13, 16:11
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54533184&newsitemid=20260510786927&lan=en-US&anc
May 12, 14:30
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De Novo request to the U.S. Food and Drug Administration seeking
May 12, 10:15
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulatio
Urethral stricture starts with narrowing of a short segment of urethral lumen. At early stages, it i
May 11, 16:50
Pioneering feat in regenerative medicine, the BEES-HAUS cell therapy: Paracrine effect and cell engraftment, together healing urethral stricture. Its simplified version, BHES-HAUS’ results to be presented in AUA 2026
A path breaking scientific discovery, unraveling successful wound healing mechanism in urethral stricture with BEES-HAUS (https://www.ncrm.org/myth/beeshaus/) cell therapy has been reported by Indo-Ja
May 10, 15:25
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of
WHOOP Expands Health Platform with On-Demand Clinician Access and New AI Features
May 10, 13:30
WHOOP Expands Health Platform with On-Demand Clinician Access and New AI Features
WHOOP (https://www.whoop.com/kr/en/?utm_source=PR&utm_medium=PR&utm_campaign=SR_A), the human performance company, today announced a new suite of health and AI-driven enhancements and feature updates
HE Mansoor Al Mansoori (Left) and Tom Hale (Right)
May 08, 16:50
Department of Health - Abu Dhabi and ŌURA Partner to Advance Preventive Health in Abu Dhabi
Department of Health—Abu Dhabi (https://www.doh.gov.ae/en/) (DoH) and ŌURA (https://ouraring.com/ko?srsltid=AfmBOormyEZs4LuQCQfSGbmxbAuvAy4qBM3q7akrgnjiPIzDNqS2nZh9), maker of the world’s leading smar
May 06, 16:25
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), m
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Mo
May 04, 16:00
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Wid
May 03, 17:20
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership
CorFlow Therapeutics AG (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.corflow.com&esheet=54526078&newsitemid=20260430413675&lan=en-US&anchor=CorFlow+Therapeutics+AG&index=1&md5
May 03, 16:00
MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis
MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH
May 03, 11:40
SS&C Unveils WorkHQ to Power Enterprise Agentic Automation
SS&C Technologies Holdings, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ssctech.com%2F%3Futm_campaign%3DSSC2026-Enterprise-Press-Release-0426%26utm_medium%3Dpressreleas
May 03, 11:00
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54524717&newsitemid=20260429582815&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
May 03, 10:40
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal
David Weinreich, Global Head of R&D and Chief Medical Officer
May 03, 10:20
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481 (https://cts.businesswire.com/ct/CT?id=smartlink&url=h
Masimo RD SET® Neo Pulse Oximetry Sensor
April 30, 16:10
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study
Masimo (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54524005&newsitemid=20260428136753&lan=en-US&anchor=Masimo&index=1&md5=9061676d45e4b2fdccbe6887499605e3)
Dr. Vivek Mundada with Medcare multidisciplinary medical team (Photo: AETOSWire)
April 30, 09:40
Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US
Medcare Royal Speciality Hospital (MRSH) in Dubai has become the world’s first hospital outside the USA, to offer a newly licensed intrathecal gene therapy - Itvisma, to adult patients with Spinal Mus
Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equi
April 30, 08:55
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), today announced that the compan
Credits to Roquette
April 29, 17:15
Roquette Showcases Its Expanded Consumer Healthcare Capabilities at Vitafoods Europe 2026
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will present its expanded portfolio at Vitafoods Europe 2026 which is taking place from May 5 to May 7 in
April 29, 13:13
Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific
Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as “ATLATL”), global innovation platform for life science research and development, today announced that the companies h
25 per page50 per page75 per page100 per page